繁體中文 简体中文

研究發表

108年度研究論文

篇序

作者
(順位)

論文題目 發表雜誌名稱
(
含年月/卷期/頁次)
屬性
(SCI、SSCI、IEEE)
1 湯宏仁(3) Implementation of a national quality improvement program to enhance hand hygiene in nursing homes in Taiwan.  J Microbiol Immunol Infect. 2019 Apr;52(2):345-351 SCI 
2 湯宏仁(2) Bloodstream infections in hospitalized adults with dengue fever: Clinical characteristics and recommended empirical therapy.  J Microbiol Immunol Infect. 2019 Apr;52(2):225-232 SCI 
3 湯宏仁(2) The Microbiological Characteristics of Carbapenem-Resistant Enterobacteriaceae Carrying the mcr-1 Gene.  J Clin Med. 2019 Feb 19;8(2) SCI 
4 湯宏仁(1) Emergence of multidrug-resistant Candida auris in Taiwan.  Int J Antimicrob Agents. 2019 May;53(5):705-706  SCI
5 湯宏仁(4,C) Echinocandins vs. amphotericin B against invasive candidiasis in children and neonates: A meta-analysis of randomized controlled trials.  Int J Antimicrob Agents. 2019 Jun;53(6):789-794  SCI
6 湯宏仁(4,C) The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials.  Infect Drug Resist. 2019 Feb 14;12:433-438  SCI
7 湯宏仁(3) Antimicrobial activities of ceftazidime-avibactam, ceftolozane-tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016. Infect Drug Resist. 2019 Mar 4;12:545-552  SCI
8 湯宏仁(1) Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: Combination of tigecycline or doxycycline and gentamicin or amikacin. J Microbiol Immunol Infect. 2019 Apr;52(2):273-281  SCI
9 湯宏仁(7) Taiwan HIV Study Group. Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia. AIDS. 2019 Jul 1;33(8):1345-1351  SCI
10 湯宏仁(4) Susceptibility rates of clinically important bacteria collected from intensive care units against colistin, carbapenems, and other comparative agents: results from Surveillance of Multicenter Antimicrobial Resistance in Taiwan  Infect Drug Resist. 2019 Mar 14;12:627-640  SCI
11 湯宏仁(9,C) Antimicrobial Activity of Lactobacillus Species Against Carbapenem-Resistant Enterobacteriaceae. Front Microbiol. 2019 Apr 18;10:789  SCI
12 湯宏仁(6) Short versus long duration antimicrobial treatment for community-onset bacteraemia: A propensity score matching study.  Int J Antimicrob Agents. 2019 Aug;54(2):176-183  SCI
13 湯宏仁(9) Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia. Antimicrob Agents Chemother. 2019 Jul 25;63(8)   SCI
14 湯宏仁(4) The efficacy and safety of ceftaroline in the treatment of acute bacterial infection in pediatric patients - a systemic review and meta-analysis of randomized controlled trials.  Infect Drug Resist. 2019 May 15;12:1303-1310  SCI
15 湯宏仁(7) Clinical manifestations of candidemia caused by uncommon Candida species and antifungal susceptibility of the isolates in a regional hospital in Taiwan, 2007-2014. Format:  J Microbiol Immunol Infect. 2019 Aug;52(4):612-619  SCI
16 湯宏仁(1) Lefamulin for treating community-acquired bacterial pneumonia in adult patients aged < 65 years. Clin Infect Dis. 2019 Dec 11. pii: ciz1173. doi: 10.1093/cid/ciz1173. [Epub ahead of print]  SCI
17 湯宏仁(6) Beneficial effects of early empirical administration of appropriate antimicrobials on survival and defervescence in adults with community-onset bacteremia. Crit Care. 2019 Nov 20;23(1):363  SCI
18 湯宏仁(5) Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan. Antibiotics (Basel). 2019 Nov 10;8(4)  SCI
19 湯宏仁(1) Plazomicin-associated nephrotoxicity. Clin Infect Dis. 2019 Oct 26. pii: ciz1064. doi: 10.1093/cid/ciz1064. [Epub ahead of print]  SCI
20 湯宏仁(2) Warning signs and severe dengue in end stage renal disease dialysis patients. J Microbiol Immunol Infect. 2019 Sep 30. pii: S1684-1182(19)30137-9. doi: 10.1016/j.jmii.2019.08.005. [Epub ahead of print]  SCI
21 湯宏仁(2) Determining the clinical characteristics and prognostic factors for the outcomes of Japanese encephalitis in adults: A multicenter study from southern Taiwan. J Microbiol Immunol Infect. 2019 Dec;52(6):893-901 SCI
22 湯宏仁(9,C) The Potential Role of Sulbactam and Cephalosporins Plus Daptomycin Against Daptomycin-Nonsusceptible VISA and H-VISA Isolates: An in Vitro Study. Antibiotics (Basel). 2019 Oct 14;8(4) SCI
23 湯宏仁(3,C) Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections. J Clin Med. 2019 Oct 11;8(10) SCI
24 湯宏仁(6) Timing of follow-up blood cultures for community-onset bacteremia. Sci Rep. 2019 Oct 10;9(1):14500 SCI
25 湯宏仁(1) The safety of eravacycline in the treatment of acute bacterial infection. Clin Infect Dis. 2019 Aug 29 SCI
26 湯宏仁(6) Clinical Benefit of Empiric High-Dose Levofloxacin Therapy for Adults With Community-onset Enterobacteriaceae Bacteremia. Clin Ther. 2019 Oct;41(10):1996-2007. SCI
27 湯宏仁(4,C) The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections-A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2019 Jul 2;8(7) SCI
28 湯宏仁(4) The efficacy and safety of ceftaroline in the treatment of acute bacterial infection in pediatric patients - a systemic review and meta-analysis of randomized controlled trials. Infect Drug Resist. 2019 May 15;12:1303-1310 SCI
29 湯宏仁(9) Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia. Antimicrob Agents Chemother. 2019 Jul 25;63(8) SCI
30 湯宏仁(6) Short versus long duration antimicrobial treatment for community-onset bacteraemia: A propensity score matching study. Int J Antimicrob Agents. 2019 Aug;54(2):176-183 SCI
31 湯宏仁(4) Susceptibility rates of clinically important bacteria collected from intensive care units against colistin, carbapenems, and other comparative agents: results from Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART). Infect Drug Resist. 2019 Mar 14;12:627-640 SCI
32 湯宏仁(3) Antimicrobial activities of ceftazidime-avibactam, ceftolozane-tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016. Infect Drug Resist. 2019 Mar 4;12:545-552 SCI
33 湯宏仁(4,C) The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials. Infect Drug Resist. 2019 Feb 14;12:433-438 SCI
34 湯宏仁(4,C) Echinocandins vs. amphotericin B against invasive candidiasis in children and neonates: A meta-analysis of randomized controlled trials. Int J Antimicrob Agents. 2019 Jun;53(6):789-794 SCI
35 湯宏仁(1) Emergence of multidrug-resistant Candida auris in Taiwan. Int J Antimicrob Agents. 2019 May;53(5):705-706 SCI
36 湯宏仁(2) The Microbiological Characteristics of Carbapenem-Resistant Enterobacteriaceae Carrying the mcr-1 Gene. J Clin Med. 2019 Feb 19;8(2) SCI
37 湯宏仁(2) Bloodstream infections in hospitalized adults with dengue fever: Clinical characteristics and recommended empirical therapy. J Microbiol Immunol Infect. 2019 Apr;52(2):225-232 SCI
38 湯宏仁(3) Implementation of a national quality improvement program to enhance hand hygiene in nursing homes in Taiwan. J Microbiol Immunol Infect. 2019 Apr;52(2):345-351 SCI
39 湯宏仁(7) Clinical manifestations of candidemia caused by uncommon Candida species and antifungal susceptibility of the isolates in a regional hospital in Taiwan, 2007-2014. J Microbiol Immunol Infect. 2019 Aug;52(4):612-619 SCI
40

陳宏睿(1)

湯宏仁(2)

同性戀螺桿菌感染引起之菌血症-一個被忽略的愛滋病患發燒病因 Journal of Biomedical & Laboratory Sciences;31卷4期 (2019 / 12 / 31),P131 - 137 SCI
41 湯宏仁(6) Warning signs and severe dengue in end stage renal disease dialysis patients J Microbiol Immunol Infect. 2019 Sep 30. pii: S1684-1182(19)30137-9 SCI